Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

something that is compromised in skin conditions like psoriasis, eczema and severe dryness. According to Stull, vitamin ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Your psoriasis is severe when it covers more than 10% of your body or happens on your face, palms, or soles of your feet. While there's no cure, there are treatments that can help. For severe ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...

Medically reviewed by Brendan Camp, MD Psoriasis affects about 3% of all adults in the United States, and Asian Americans ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...